Global $53 Billion Regenerative Medicine Market Analysis & Forecast Report 2017-2021: Focus on Stem Cells, Tissue Engineering, BioBanking & CAR-T Industries

5/12/2017, 2:39 PM (Source: GlobeNewswire)

Dublin, May 12, 2017 (GLOBE NEWSWIRE) -- Research and Markets has announced the addition of the "Global Regenerative Medicine Market Analysis & Forecast to 2021 - Stem Cells, Tissue Engineering, BioBanking & CAR-T Industries" report to their offering.

Current regenerative medicine market is worth $18.9 billion globally, and will hit over $53 billion by 2021

According to the report ‘due to the dominance of the bone and joint reconstruction market, the US currently has the biggest space, followed by Europe. However, due to recent positive legislation in Japan and Europe, the stem cell arena will grow more substantially in these regions over the next five years. By 2021, it is possible that Europe will surpass the US market with respect to stem cell applications, and this will become more likely if the Trump Administration restricts legislation and funding’.

The regenerative medicine market has massive scope and can be applied to a wide range of diseases and indications including neurological, autoimmune, cardiovascular, diabetes, musculoskeletal, ocular, orthopedic and wound healing. To that end, the expanse of market opportunities is large as are the patient populations globally. Kelly indicates that ‘this study has extensively profiled all major players in the market, analyzed their financials, pipeline products and business strategy going forward. It is the most comprehensive analysis on the market, and stakeholders wanting to gain a significant insight would greatly benefit from this information’.

Financial forecasts to 2021 are included with respect to:

  • Global regenerative medicine market, global breakdown, application breakdown and leading market players
  • Global stem cell industry market by geography and indication
  • Global tissue engineering market by geography and indication
  • Global Biobanking market sector analysis and breakdown

Interestingly, the report also takes a detailed look at the CAR-T industry and its impact on the healthcare space. The CAR-T industry is addressing unmet needs in specific relapsed cancers, however does early clinical trial data support a blockbuster status for this upcoming therapy?

The report also addresses the following key points:

  • Challenges Relating to Cell therapy and Chimeric Antigen Receptor T Cells in Immunotherapy
  • Key Regulatory and Manufacturing Challenges Associated with CAR-T Development
  • Autologous Cell Therapy Manufacture Scale Up
  • Supply Chain Logistics, Pricing & Cost Analysis
  • CAR T Therapy Market Evaluation

Key stakeholder questions are answered in this 680 page analysis including:

  • What disruptive technology is advancing the overall regenerative medicine market?
  • What are the major company players in the regenerative medicine, stem cells, tissue engineering and CAR-T industries?
  • What types of clinical trials are currently being performed by stakeholders and major players?
  • What are the global access challenges of the regenerative medicine market?
  • What is the space like in Japan, China, South Korea, USA and Europe?
  • What are the advantages and disadvantages of the allogenic and autologous stem cell industry?
  • What are the main restraints of the regenerative medicine industry as a whole?
  • What is the current environment of the global cord blood bank industry?
  • What are the global access challenges of the regenerative medicine market?
  • What is the space like in Japan, China, South Korea, USA and Europe?
  • Why do stem cell clinical trials fail?
  • What is the future of stem cell trials?
  • What manufacturing strategies can be used for stem cell products?

Key Topics Covered:

1.0 Report Synopsis
1.1 Objectives of Report
1.2 Executive Summary
1.2 Key Questions Answered in this Report
1.3 Data Sources and Methodology

2.0 Introduction
2.1 Gurdon and Yamanaka Share the Nobel Prize
2.2 Stem Cell Clinical Trials: Initiated in 2010
2.3 Types of Stem Cells
2.4 Adult (Tissue) Stem Cells
2.5 Pluripotent Stem Cells
2.6 Somatic Cell Nuclear Transfer (SCNT)
2.7 Induced pluripotent Stem Cells (iPSC)
2.8 Mesenchymal Cells
2.9 Hematopoietic Stem and Progenitor Cells
2.10 Umbilical Cord Stem Cells
2.11 Heart Stem Cells
2.12 Mammary Stem Cells
2.13 Neural Stem Cells
2.14 Stem Cell Applications in Retinal Repair
2.15 Liver Stem Cells
2.16 Gut Stem Cells
2.16 Pancreatic Stem Cells
2.17 Epidermal Stem Cells

3.0 Stem Cells and Clinical Trials
3.1 Introduction
3.2 Pluripotent Stem Cells
3.3 Limbal Stem Cells
3.4 Neural Stem Cells
3.5 Endothelial Stem or Progenitor Cells
3.6 Placental Stem Cells
3.7 Why Do Stem Cell Clinical Trials Fail?
3.8 What is the Future of Stem Cell Trials?
3.9 Cutting Edge Stem Cell Clinical Trials
3.10 Ocata Therapeutics Current Stem Cell Trials
3.11 CHA Biotech Current Stem Cell Trials
3.12 Pfizer Current Stem Cell Trials
3.13 GSK Current Stem Cell Trials
3.14 Bayer Current Stem Cell Trials
3.15 Mesoblast International Current Stem Cell Trials
3.16 Millennium Pharmaceutical Current Stem Cell Trial
3.17 AstraZeneca Current Stem Cell Trials
3.18 Merck Current Stem Cell Trials
3.19 Chimerix Current Stem Cell Trials
3.20 Eisai Current Stem Cell Trials
3.21 SanBio Current Stem Cell Trials
3.22 Celgene Current Stem Cell Trials
3.23 StemCells Current Stem Cell Trials
3.24 Genzyme (Sanofi) Current Stem Cell Trials
3.25 Teva Current Stem Cell Trials
3.26 MedImmune Current Stem Cell Trials
3.27 Janssen Current Stem Cell Trials
3.28 Seattle Genetics Current Stem Cell Trials
3.29 Baxter Healthcare Current Stem Cell Trials
3.30 InCyte Corp Current Stem Cell Trials

4.0 Stem Cells, Disruptive Technology, Drug Discovery & Toxicity Testing
4.1 Introduction
4.2 Case Study: Genentech and Stem Cell Technology
4.3 3D Sphere Culture Systems
4.4 Stem Cells and High Throughput Screening
4.5 Genetic Instability of Stem Cells
4.6 Comprehensive in Vitro Proarrhythmia Assay (CiPA) & Cardiomyocytes
4.8 Coupling Precise Genome Editing (PGE) and iPSCs
4.9 Stem Cells & Toxicity Testing
4.10 Stem Cell Disease Models
4.11 Defining Human Disease Specific Phenotypes
4.12 Advantages of Stem Cell Derived Cells & Tissues for Drug Screening

5.0 Stem Cell Biomarkers
5.1 Pluripotent Stem Cell Biomarkers
5.2 Mesenchymal Stem Cell Biomarkers
5.3 Neural Stem Cell Biomarkers
5.4 Hematopoietic Stem Cell Biomarkers

6.0 Manufacturing Stem Cell Products
6.1 Manufacturing Strategies For Stem Cell Products
6.2 BioProcess Economics for Stem Cell Products
6.3 Capital Investment
6.4 Cost of Goods
6.5 Bioprocess Economic Drivers & Strategies
6.6 hPSC Expansion & Differentiation using Planar Technology
6.7 hPSC Expansion using 3D Culture
6.8 Microcarrier Systems
6.9 Aggregate Suspension
6.10 Bioreactor Based Differentiation Strategy
6.11 Integrated hPSC Bioprocess Strategy
6.12 GMP Regulations and Stem Cell Products

7.0 Investment & Funding
7.1 What do Investors Want from Cell & Gene Therapy Companies?
7.2 What Makes a Good Investment?
7.3 What Types of Companies do Not Get Investment?
7.4 Global Funding
7.5 Cell & Gene Therapy Investment Going Forward
7.6 What Cell & Gene Companies are the Most Promising in 2017?
7.7 Insights into Investing in Cell and Gene Therapy Companies

8.0 Regenerative Medicine Market Analysis & Forecast to 2021
8.1 Market Overview
8.2 Global Frequency Analysis
8.3 Economics of Regenerative Medicine
8.4 Market Applications & Opportunities for Regenerative Therapies
8.5 Global Financial Landscape
8.6 Regenerative Medicine Clinical Trial Statistics
8.7 Regenerative Medicine Market Forecast to 2021
8.8 Regenerative Medicine Geographic Analysis and Forecast to 2021
8.9 Regenerative Medicine Geographical Location of Companies
8.10 Regenerative Medicine Technology Breakdown of Companies
8.11 Commercially Available Regenerative Medicine Products
8.12 Major Regenerative Medicine Milestones

9.0 Stem Cell Market Analysis & Forecast to 2021
9.1 Autologous & Allogenic Cell Market Analysis
9.2 Stem Cell Market by Geography
9.3 Stem Cell Market Forecast by Therapeutic Indication
9.4 Stem Cell Reagent Market Trends

10.0 Tissue Engineering Tissue Engineering Market Analysis and Forecast to 2021
10.1 Geographical Analysis and Forecast to 2021
10.2 Geographical Analysis by Company Share
10.3 Tissue Engineering Clinical Indication Analysis & Forecast to 2021

11.0 Biobanking Market Analysis
11.1 Increasing Number of Cord Blood Banks Globally
11.2 Global Biobanking Company Sector Analysis & Breakdown
11.3 Allogenic Versus Autologous Transplant Frequency
11.4 Biobanking Market Analysis & Forecast to 2021
11.5 Major Global Players

12.0 Global Access & Challenges of the Regenerative Medicine Market
12.1 Regenerative Medicine Market in the USA
12.2 Regenerative Medicine in Japan
12.3 Regenerative Medicine in China
12.4 Regenerative Medicine in South Korea

13.0 Cell and CAR T Therapy
13.1 Challenges Relating to Cell therapy and Chimeric Antigen Receptor T Cells in Immunotherapy
13.2 Regulations Pertaining to Immunotherapy, including Adoptive Cell Therapy (CAR-T and TCR) Immunotherapy Regulation in the USA
13.3 Regulations for Cell Therapy & Immunotherapy in Japan
13.4 European Regulation and Cell Therapy & Immunotherapeutics
13.5 Manufacturing of Immunotherapies
13.6 Supply Chain & Logistics
13.7 Pricing & Cost Analysis

14.0 Company Profiles
14.1 Astellas Institute for Regenerative Medicine (Ocata Therapeutics)
14.2 Athersys
14.3 Baxter International (Baxalta, Shire)
14.4 Caladrius Biosciences (NeoStem)
14.5 Cynata Therapeutics
14.6 Cytori Therapeutics
14.7 MEDIPOST
14.8 Mesoblast
14.9 NuVasive
14.10 Osiris Therapeutics
14.11 Plasticell
14.12 Pluristem Therapeutics
14.13 Pfizer
14.14 StemCells Inc
14.15 STEMCELL Technologies
14.16 Takara Bio
14.17 Tigenix

15.0 SWOT Industry Analysis

For more information about this report visit http://www.researchandmarkets.com/research/ml94n2/global




CONTACT: Research and Markets
         Laura Wood, Senior Manager
         press@researchandmarkets.com
         For E.S.T Office Hours Call 1-917-300-0470
         For U.S./CAN Toll Free Call 1-800-526-8630
         For GMT Office Hours Call +353-1-416-8900
         U.S. Fax: 646-607-1907
         Fax (outside U.S.): +353-1-481-1716
         Related Topics: Biopharmaceuticals , Stem Cells , Biomaterials 

Primary Logo

Copyright GlobeNewswire, Inc. 2016. All rights reserved.
You can register yourself on the website to receive press releases directly via e-mail to your own e-mail account.